![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AZ Fizzles in Phase 3 Trial for Cancer Drug Selumetinib
AZ Fizzles in Phase 3 Trial for Cancer Drug Selumetinib
AstraZeneca has revealed that its cancer drug candidate selumetinib fell short in a Phase 3 trial.
The company said the drug did not meet its primary endpoint of progression-free survival in patients when tested in combination with docetaxel chemotherapy.
AstraZeneca said it will present data from the study at a medical conference at some unspecified point in the future.
Upcoming Events
-
21Oct